Continuous hemodialfiltration using PMMA membrane: clinical efficacy and its mechanisms.
Moriyama
K
K
Artificial Organs Operations and Planning Department, Toray Industries, Inc. Tokyo, Japan. kazuhiro-moriyama@nts.toray.co.jp
Soejima
Y
Y
D001672:Biocompatible Materials; D001685:Biological Factors / Q000378:metabolism; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000166:cytology; D017583:Hemodiafiltration / Q000295:instrumentation*; D006801:Humans; D007239:Infections / Q000150:complications; D007249:Inflammation / Q000097:blood / Q000209:etiology; D007564:Japan / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000453:epidemiology / Q000628:therapy; D008567:Membranes, Artificial; D008657:Metabolic Clearance Rate; D008970:Molecular Weight; D009102:Multiple Organ Failure / Q000209:etiology / Q000517:prevention & control; D009569:Nitric Oxide / Q000096:biosynthesis; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D019904:Polymethyl Methacrylate
D001672:Biocompatible Materials; D001685:Biological Factors; D016207:Cytokines; D008567:Membranes, Artificial; D009569:Nitric Oxide; D019904:Polymethyl Methacrylate; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III